

Supramaximal Dose of Candesartan in Proteinuric Renal

Journal of the American Society of Nephrology: JASN
20, 893-900

DOI: [10.1681/asn.2008040416](https://doi.org/10.1681/asn.2008040416)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. <i>Vascular Health and Risk Management</i> , 2009, 5, 1043.	1.0	12
3	Drug Dosing for Renoprotection. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 688-689.	3.0	7
4	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040.	1.0	46
5	Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. <i>Current Medical Research and Opinion</i> , 2009, 25, 2933-2949.	0.9	6
6	Reducing cardiovascular risk: protecting the kidney. <i>European Heart Journal Supplements</i> , 2009, 11, F39-F46.	0.0	2
7	Increased angiotensin-receptor blocking is not the first option. <i>Nature Reviews Nephrology</i> , 2009, 5, 367-368.	4.1	12
8	Candesartan: widening indications for this angiotensin II receptor blocker?. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1995-2007.	0.9	5
9	Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney. <i>Current Medicinal Chemistry</i> , 2009, 16, 3701-3715.	1.2	26
10	Mineralocorticoid Receptor Blockers and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1685-1691.	2.2	31
11	Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. <i>Current Hypertension Reports</i> , 2009, 11, 345-353.	1.5	6
13	Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. <i>Journal of Hypertension</i> , 2010, 28, 520-526.	0.3	12
14	Can we slow the progression of chronic kidney disease?. <i>Current Opinion in Pediatrics</i> , 2010, 22, 170-175.	1.0	15
15	Supramaximal Dose of Candesartan in Proteinuric Renal Disease. <i>Yearbook of Medicine</i> , 2010, 2010, 208-210.	0.1	1
17	Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. <i>Journal of Hypertension</i> , 2010, 28, 1083-1090.	0.3	67
19	When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes. <i>Pediatric Nephrology</i> , 2010, 25, 2021-2034.	0.9	5
20	Comparing angiotensin II receptor blockers on benefits beyond blood pressure. <i>Advances in Therapy</i> , 2010, 27, 257-284.	1.3	17
21	Dual Renin-Angiotensin-Aldosterone System Blockade for Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2010, 10, 297-305.	1.7	22
22	Chronic Kidney Disease and Albuminuria in Arterial Hypertension. <i>Current Hypertension Reports</i> , 2010, 12, 335-341.	1.5	13

#	ARTICLE	IF	CITATIONS
23	Application of Direct Renin Inhibition to Chronic Kidney Disease. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 139-149.	1.3	33
24	Dual renin-angiotensin-aldosterone system inhibition: boon or bust?. <i>International Journal of Clinical Practice</i> , 2010, 64, 1337-1340.	0.8	0
25	Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection. <i>Nephrology</i> , 2010, 15, 57-60.	0.7	11
26	Cardio classics revisited – focus on the role of candesartan. <i>Vascular Health and Risk Management</i> , 2010, 6, 1047.	1.0	2
27	Stage IV Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1942-1943.	13.9	0
29	The RAAS in the pathogenesis and treatment of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2010, 6, 319-330.	4.1	252
30	Which antihypertensive drugs are the most nephroprotective and why?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2651-2663.	0.9	19
32	Treating high blood pressure: Is reaching the target more important than the means? No, the means are important. <i>European Journal of Internal Medicine</i> , 2010, 21, 478-483.	1.0	0
34	Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2. <i>Kidney International</i> , 2010, 78, 69-78.	2.6	40
35	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 57-60.	0.6	0
36	Therapeutic Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone-System Pathway. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 290-299.	0.6	13
38	Hypertension augments cardiac Toll-like receptor 4 expression and activity. <i>Hypertension Research</i> , 2011, 34, 551-558.	1.5	90
39	Editorial World Kidney Day 2011: Protect your kidneys, save your heart. <i>Archives of Medical Science</i> , 2011, 1, 1-4.	0.4	12
40	World Kidney Day 2011: protect your kidneys, save your heart. <i>Medical Journal of Australia</i> , 2011, 194, 225-227.	0.8	1
41	Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). <i>Vascular Health and Risk Management</i> , 2011, 7, 85.	1.0	8
42	Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. <i>Journal of Hypertension</i> , 2011, 29, 1228-1235.	0.3	14
43	World Kidney Day 2011: Protect your kidneys, save your heart. <i>Nephrology</i> , 2011, 16, 121-124.	0.7	1
44	World Kidney Day 2011: protect your kidneys, save your heart. <i>Internal Medicine Journal</i> , 2011, 41, 140-143.	0.5	0

#	ARTICLE	IF	CITATIONS
45	Drug of Choice in the Management of Hypertension in Diabetes and Diabetic Nephropathy: Angiotensinâ€‘Converting Enzyme Inhibitors. Journal of Clinical Hypertension, 2011, 13, 285-289.	1.0	3
46	Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. Journal of Clinical Hypertension, 2011, 13, 848-855.	1.0	4
47	Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology, 2011, 36, 1-18.	1.3	217
48	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Hong Kong Journal of Nephrology, 2011, 13, 1-4.	0.0	0
49	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. American Journal of Kidney Diseases, 2011, 57, 371-374.	2.1	2
51	Phase IV, 8-Week, Multicenter, Randomized, Active Treatmentâ€‘Controlled, Parallel Group, Efficacy, and Tolerability Study of High-Dose Candesartan Cilexetil Combined With Hydrochlorothiazide in Korean Adults With Stage II Hypertension. Clinical Therapeutics, 2011, 33, 1043-1056.	1.1	6
52	World Kidney Day 2011: Protect your kidneys, save your heart. Pediatric Nephrology, 2011, 26, 329-332.	0.9	0
53	Drug-Induced Changes in Risk/Biomarkers and Their Relationship with Renal and Cardiovascular Long-Term Outcome in Patients with Diabetes. Clinical Chemistry, 2011, 57, 186-195.	1.5	4
54	Monitoring Kidney Function and Albuminuria in Patients With Diabetes. Diabetes Care, 2011, 34, S325-S329.	4.3	42
55	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Blood Purification, 2011, 32, 53-56.	0.9	1
56	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Kidney and Blood Pressure Research, 2011, 34, 135-138.	0.9	0
57	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 235-238.	2.2	6
58	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. American Journal of Nephrology, 2011, 33, 193-196.	1.4	1
59	Unmet Need in Renal Protection â€‘ Do We Need a More Comprehensive Approach?. Contributions To Nephrology, 2011, 171, 157-160.	1.1	22
60	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. European Heart Journal, 2011, 32, 1493-1499.	1.0	115
61	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Nephrology Dialysis Transplantation, 2011, 26, 395-398.	0.4	0
62	Combination inhibition of the reninâ€‘angiotensin system: is more better?. Kidney International, 2011, 80, 245-255.	2.6	15
63	Reninâ€‘angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy, 2011, 9, 1585-1591.	0.6	7

#	ARTICLE	IF	CITATIONS
64	The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. <i>Kidney International</i> , 2011, 80, 1258-1270.	2.6	1,105
65	Managing kidney disease with blood-pressure control. <i>Nature Reviews Nephrology</i> , 2011, 7, 434-444.	4.1	37
66	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. <i>Nephron Clinical Practice</i> , 2011, 117, I-IV.	2.3	1
67	Inhibition of renin activity slows down the progression of HIV-associated nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F711-F720.	1.3	13
68	Potential role of urinary angiotensinogen in predicting antiproteinuric effects of angiotensin receptor blocker in non-diabetic chronic kidney disease patients: a preliminary report. <i>Postgraduate Medical Journal</i> , 2012, 88, 210-216.	0.9	17
69	Retarding the progression of chronic kidney disease with renin angiotensin system blockade. <i>Indian Journal of Nephrology</i> , 2012, 22, 108.	0.2	7
72	A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications. <i>Current Hypertension Reviews</i> , 2012, 8, 196-226.	0.5	2
73	Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disorders. <i>Clinical Science</i> , 2012, 123, 567-590.	1.8	168
74	Sexual Dimorphism in Urinary Angiotensinogen Excretion During Chronic Angiotensin II Salt Hypertension. <i>Gender Medicine</i> , 2012, 9, 207-218.	1.4	23
75	Regression of Atherosclerosis in Apolipoprotein E-Deficient Mice is Feasible Using High-Dose Angiotensin Receptor Blocker, Candesartan. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, .	0.9	4
76	Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. <i>Journal of General Internal Medicine</i> , 2012, 27, 458-468.	1.3	46
78	Improving the efficacy of RAAS blockade in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2013, 9, 112-121.	4.1	51
79	Optimal renin-angiotensin system blockade wishful thinking?. <i>Nature Reviews Cardiology</i> , 2013, 10, 486-486.	6.1	2
80	La néphropathie chronique en présence de diabète. <i>Canadian Journal of Diabetes</i> , 2013, 37, S504-S512.	0.4	1
81	Progression of chronic kidney disease: Mechanisms and interventions in retardation. <i>Apollo Medicine</i> , 2013, 10, 19-28.	0.0	8
82	Chronic Kidney Disease in Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, S129-S136.	0.4	53
83	Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 273-282.	1.0	9
84	Dose-Dependent Arterial Destiffening and Inward Remodeling After Olmesartan in Hypertensives With Metabolic Syndrome. <i>Hypertension</i> , 2014, 64, 709-716.	1.3	88

#	ARTICLE	IF	CITATIONS
85	Treatment Strategies to Prevent Renal Damage in Hypertensive Children. Current Hypertension Reports, 2014, 16, 423.	1.5	3
86	Sequential RAAS Blockade: Is It Worth the Risk?. Advances in Chronic Kidney Disease, 2014, 21, 159-165.	0.6	11
87	Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy. ESC Heart Failure, 2015, 2, 129-138.	1.4	15
88	The appropriate dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?. ESC Heart Failure, 2015, 2, 103-105.	1.4	8
89	Nuclear expression of renin-angiotensin system components in NRK-52E renal epithelial cells. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1135-1148.	1.0	26
90	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. British Journal of Clinical Pharmacology, 2015, 80, 678-686.	1.1	37
91	Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. Journal of Clinical Medicine, 2015, 4, 1908-1937.	1.0	40
92	A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. Clinical Therapeutics, 2015, 37, 2581-2596.e3.	1.1	13
93	Albuminuria. , 2015, , 663-673.		2
94	Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease. Chinese Medical Journal, 2016, 129, 81-87.	0.9	6
95	Differential renal effects of candesartan at high and ultra-high doses in diabetic mice—potential role of the ACE2/AT2R/Mas axis. Bioscience Reports, 2016, 36, .	1.1	32
96	Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead. Internal and Emergency Medicine, 2016, 11, 627-635.	1.0	28
97	New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease. Current Hypertension Reports, 2016, 18, 55.	1.5	6
98	Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031666843.	1.0	2
99	Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after) Tj ETQq0 0 0 rgBT /Overlock 10 Tf . Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031663389.	1.0	23
100	Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. Nephrology Dialysis Transplantation, 2016, 31, 1471-1477.	0.4	16
101	Finerenone in diabetic kidney disease — So far, so good. Journal of Diabetes and Its Complications, 2017, 31, 651-652.	1.2	3
102	Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2017, 26, 368-374.	1.0	19

#	ARTICLE	IF	CITATIONS
103	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1197-1204.	1.1	22
104	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1804-1813.	2.2	7
105	Achieving remission of proteinuria in childhood CKD. <i>Pediatric Nephrology</i> , 2017, 32, 321-330.	0.9	12
106	Chronic Kidney Disease in Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S201-S209.	0.4	57
107	Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1473-1484.	1.0	4
108	Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. <i>Blood Pressure</i> , 2019, 28, 358-374.	0.7	12
109	A Primer on Quality Assurance and Performance Improvement for Interprofessional Chronic Kidney Disease Care: A Path to Joint Commission Certification. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 83.	0.6	4
111	Renal outcomes of treatment with telmisartan in patients with stage 3-4 chronic kidney disease: A prospective, randomized, controlled trial (JINNAGA). <i>SAGE Open Medicine</i> , 2020, 8, 205031212097350.	0.7	1
112	Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2192-2203.	1.1	7
113	Late intervention in the remnant kidney model attenuates proteinuria but not glomerular filtration rate decline. <i>Nephrology</i> , 2021, 26, 270-279.	0.7	4
114	Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 173-184.	0.9	4
115	Therapeutic Insights in Chronic Kidney Disease Progression. <i>Frontiers in Medicine</i> , 2021, 8, 645187.	1.2	38
116	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. <i>Kidney International</i> , 2021, 99, S1-S87.	2.6	497
117	Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease. , 2011, , 1918-1971.		5
118	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0029.	0.4	3
119	Emerging strategies to preserve renal function. <i>Journal of Nephrology</i> , 2011, 24, 133-141.	0.9	11
120	Renal protection with angiotensin receptor blockers: where do we stand. <i>Journal of Nephrology</i> , 2011, 24, 569-580.	0.9	20
121	Angiotensin-Receptor Blockers in the Prevention or Treatment of Microalbuminuria. <i>Annals of Internal Medicine</i> , 2009, 151, 63.	2.0	2

#	ARTICLE	IF	CITATIONS
122	Perspectives of using angiotensin receptor antagonists. Systemic Hypertension, 2009, 6, 38-43.	0.1	0
123	Hemmstoffe des Renin-Angiotensin-Systems. , 2010, , 219-252.		0
125	Hemmstoffe des Renin-Angiotensin-Systems. , 2011, , 225-260.		0
126	World Kidney Day 2011: Protect Your Kidneys, Save Your Heart. Transplantation, 2011, 91, 383-385.	0.5	1
127	Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms. , 2012, , 249-266.		0
128	A Stepped Care Approach to the Management of Chronic Kidney Disease. , 2012, , 2205-2239.		1
129	Hemmstoffe des Renin-Angiotensin-Systems. , 2012, , 225-262.		0
130	Prevention and Regression of Chronic Kidney Disease and Hypertension. , 0, , .		0
131	Hemmstoffe des Renin-Angiotensin-Systems. , 2013, , 217-256.		0
132	Hemmstoffe des Renin- Angiotensin-Systems. , 2014, , 259-300.		0
133	Hemmstoffe des Renin-Angiotensin-Systems. , 2015, , 267-309.		1
134	Progression of Chronic Kidney Disease and Nephroprotective Therapy. , 2016, , 1399-1423.		1
135	Hemmstoffe des Renin-Angiotensin-Systems. , 2016, , 209-235.		0
136	Hemmstoffe des Renin-Angiotensin-Systems. , 2017, , 211-236.		0
137	Unpuzzling the Comorbid Type 2 Diabetes and Hypertension-Related Cognitive Dysfunction and Stroke. Springer Series in Translational Stroke Research, 2017, , 711-731.	0.1	1
138	CANDESARTAN IN CARDIOLOGY PRACTICE. Meditsinskiy Sovet, 2017, , 12-16.	0.1	0
139	CANDESARTAN IN CARDIOLOGY PRACTICE. Meditsinskiy Sovet, 2017, , 12-16.	0.1	1
140	Hemmstoffe des Renin-Angiotensin-Systems. , 2018, , 263-288.		0

#	ARTICLE	IF	CITATIONS
141	Fixed combinations in modern hypertension treatment algorithms. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 86-94.	0.4	1
143	World kidney day 2011: protect your kidneys, save your heart. International Journal of Organ Transplantation Medicine, 2011, 2, 4-8.	0.5	2
144	Efficacy and Safety of Candesartan 16 mg versus 64 mg Candesartan in Renal Disease Patients with Proteinuria: A Systematic Review and Meta-analysis. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 608-612.	0.1	1
145	The Research Status of Drugs for Chronic Kidney Disease. Pharmacy Information, 2022, 11, 234-240.	0.1	0
146	Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management. International Journal of Nephrology and Renovascular Disease, 0, Volume 15, 215-228.	0.8	8
147	Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 1148.	3.0	15
148	Effect of Telmisartan and Quercetin in 5 Fluorouracil-Induced Renal Toxicity in Rats. Journal of Inflammation Research, 0, Volume 15, 6113-6124.	1.6	2
149	Role of hypertension in progression of pediatric CKD. Pediatric Nephrology, 0, , .	0.9	0
150	Renal Hypertension: Etiology and Management. , 2023, , 1337-1362.		0
151	Progression of Chronic Kidney Disease and Nephroprotective Therapy. , 2023, , 1483-1515.		0
152	Intrarenal Renin-Angiotensin System Activation Alters Relationship Between Systolic Blood Pressure and Progression of Chronic Kidney Disease. Hypertension, 2023, 80, 1024-1034.	1.3	1